The present invention relates to the use of butyrylcholine in food and in particular in the treatment of intestinal disorders and in the stimulation of brain development. Furthermore, the invention provides for a food supplement and a pharmaceutical composition comprising butyrylcholine.

The present invention relates to a composition for preventing or treating chronic allograft dysfunction, comprising bisphosphonate which is used as a therapeutic agent for osteoporosis. The composition for preventing or treating chronic allograft dysfunction, comprising bisphosphonate, according to the present invention has an excellent prophylactic and/or therapeutic effect on chronic allograft dysfunction caused by a gradual decrease in the function of a transplanted tissue or organ which occurs after tissue or organ transplantation surgery, and thus is expected to be able to remarkably increase a long-term survival after transplantation surgery.

The present invention relates to a composition for preventing or treating chronic allograft dysfunction, comprising bisphosphonate which is used as a therapeutic agent for osteoporosis. The composition for preventing or treating chronic allograft dysfunction, comprising bisphosphonate, according to the present invention has an excellent prophylactic and/or therapeutic effect on chronic allograft dysfunction caused by a gradual decrease in the function of a transplanted tissue or organ which occurs after tissue or organ transplantation surgery, and thus is expected to be able to remarkably increase a long-term survival after transplantation surgery.

Flavoring compositions containing at least two compounds selected from the group consisting of (A) a compound represented by the formula (I):

##STR00001##

wherein each symbol is as defined in the present specification, (B) β-caryophyllene oxide, and (C) a compound represented by the formula (II):

##STR00002##

wherein each symbol is as defined in the present specification, are useful for effectively enhancing a mouth-coating feel and the like.

Described herein is a method for reducing tumor volume in a subject, the method including the steps of administering a cancer treatment (administration of at least one chemotherapeutic agent and/or application of radiation) to the subject in conjunction with the administration of choline, a choline metabolite, a choline precursor molecule, or a combination thereof. In another aspect, the disclosure relates to a method for enhancing cognitive response in a subject during cancer treatment, the method including the steps of administering cancer treatment (administration of at least one chemotherapeutic agent and/or application of radiation) to the subject in conjunction with the administration of choline, a choline metabolite, a choline precursor molecule, or a combination thereof. In still another aspect, choline, a choline metabolite, a choline precursor molecule, or a combination thereof can be administered in the form of a choline-enriched diet, a choline supplement, or a combination thereof. In some aspects, the method also enhances the effectiveness of chemotherapy.

A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.

A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.

This invention provides a peptide consisting of (i) the amino acid sequence LSSTQAQQSY (SEQ ID NO: 1), (ii) the amino acid sequence LSSTQAQQSW (SEQ ID NO: 6), or (iii) the amino acid sequence LSSTQAQQSF (SEQ ID NO: 7).

This invention provides a peptide consisting of (i) the amino acid sequence LSSTQAQQSY (SEQ ID NO: 1), (ii) the amino acid sequence LSSTQAQQSW (SEQ ID NO: 6), or (iii) the amino acid sequence LSSTQAQQSF (SEQ ID NO: 7).

Disclosed are a novel combination of specific therapeutics selected from S-adenosyl methionine or a salt thereof, folic acid or a metabolite or salt thereof, and one or more omega-3 fatty acids or salts thereof, useful for a variety of conditions, as discussed herein. Methods of treatment include the treatment of neuropsychiatric conditions, such as depression.